Cerus Corporation (CERS) is Resumed by Cantor Fitzgerald to Buy, Price Target at $9

Cerus Corporation (CERS) was Resumed by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $9. Cantor Fitzgerald advised their investors in a research report released on Jul 7, 2016.

On the company’s financial health, Cerus Corporation reported $-0.17 EPS for the quarter, based on the information available during the earnings call on May 3, 2016. Analyst had a consensus estimate of $-0.17. The company had revenue of $7.60 million for the quarter, compared to analysts expectations of $8.11 million. The company’s revenue was down -1.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.17 EPS.

Cerus Corporation (CERS) witnessed a volatile trading activity on Tuesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.27 and reached the intraday high at $6.37. The bulls started the profit booking and pushed the shares to intraday low of $6.23. The trading session was marked by a volume range of 7,01,470 shares exchanging hands. The 52-week high of the shares is $6.89 and the 52-week low is $4.27. The market cap of the company stands at $638 M and there are 10,17,10,815 shares in public circulation.

In a different news, on Mar 15, 2016, Chrystal Menard (Chief Legal Officer) sold 8,541 shares at $5.62 per share price. According to the SEC, on Sep 2, 2015, Laurence M Corash (Chief Scientific Officer) purchased 19,500 shares at $4.95 per share price.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens such as viruses including HIV West Nile SARS hepatitis B and C; bacteria and parasites as well as potentially harmful white blood cells while preserving the therapeutic properties of platelet plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries including the United States certain countries in Europe The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Cerus Corporation

Leave a Reply

Cerus Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cerus Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.